Aspire Biopharma Holdings (ASBP) Short term Debt (2023 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Short term Debt for 4 consecutive years, with $499214.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Short term Debt fell 84.28% year-over-year to $499214.0 in Q1 2026; TTM through Mar 2026 was $499214.0, a 84.28% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 89.1% from the prior year.
• Short term Debt was $499214.0 for Q1 2026 at Aspire Biopharma Holdings, down from $1.5 million in the prior quarter.
• Over five years, Short term Debt peaked at $13.8 million in Q4 2024 and troughed at $12384.0 in Q4 2023.
• A 4-year average of $3.7 million and a median of $3.4 million in 2025 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt surged 111017.34% in 2024 and sank 89.1% in 2025, its largest moves.
• Over 4 years, Short term Debt stood at $12384.0 in 2023, then surged by 111017.34% to $13.8 million in 2024, then slumped by 89.1% to $1.5 million in 2025, then tumbled by 66.72% to $499214.0 in 2026.
• The last three Short term Debt figures came in at $499214.0 (Q1 2026), $1.5 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.